Gazette.govt.nzPursuant to section 23(4A) of the Medicines Act 1981, the Minister of Health hereby renews the provisional consent to the sale, supply or use in New Zealand of the medicines set out in the Schedule hereto:
Schedule
| Product: | Mirtazapine |
| Active Ingredient: | Mirtazapine 30mg |
| Dosage Form: | Film coated tablet |
| New Zealand Sponsor: | Noumed Pharmaceuticals Limited |
| Manufacturer: | Fourrts India Laboratories Pvt Limited, Chennai, India |
|
Note: This consent is given subject to the following condition: The medicine may only be sold or supplied when no other mirtazapine medicine with consent under section 20 of the Medicines Act 1981 is available in the New Zealand market, or to meet sole tender obligations. |
|
| Note: This renewed consent is valid for two years from the date of publication of this notice. | |
| Product: | Mirtazapine |
| Active Ingredient: | Mirtazapine 45mg |
| Dosage Form: | Film coated tablet |
| New Zealand Sponsor: | Noumed Pharmaceuticals Limited |
| Manufacturer: | Fourrts India Laboratories Pvt Limited, Chennai, India |
|
Note: This consent is given subject to the following condition: The medicine may only be sold or supplied when no other mirtazapine medicine with consent under section 20 of the Medicines Act 1981 is available in the New Zealand market, or to meet sole tender obligations. |
|
| Note: This renewed consent is valid for two years from the date of publication of this notice. | |
Dated this 9th day of August 2023.
DEREK FITZGERALD, Acting Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).